Key result
Liquiritin improves NAFLD lipid metabolism in vitro by regulating the AKT/FOXO1 pathway and macrophage mitophagy.
Why the study?
Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition with a complex and multifactorial pathogenesis, prompting investigation into the mechanism of liquiritin for its treatment.
Does liquiritin improve lipid metabolism disorders in NAFLD models?
Does liquiritin improve lipid metabolism disorders in NAFLD models?
Liquiritin shows potential as a therapeutic agent for NAFLD by restoring metabolic homeostasis via the AKT1/FOXO1 signaling pathway in preclinical models.
No takes yet. Share an insight, caveat, or question.
May support liquiritin for NAFLD mechanisms; hypothesis-generating and requires clinical validation before practice change.
Zhang et al. (2026) studied Non-alcoholic fatty liver disease (NAFLD). Liquiritin vs. Free fatty acid (FFA) model was evaluated on Lipid accumulation and AKT/FOXO1 pathway modulation. Liquiritin improved NAFLD lipid metabolism disorders in vitro by regulating the AKT/FOXO1 pathway and modulating mitophagy-associated proteins in macrophages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: